Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Recombinant COVID-19 Variant Vaccine WSK-V102
NCT05765604Phase 1Completed
- Sponsor
- WestVac Biopharma
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant COVID-19 variant vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by WestVac Biopharma. Primary endpoint: Solicited Adverse Events (AE). Started Mar 2023; status: completed.
02
Drugs
recombinant COVID-19 variant vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05765604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765604.